Non-CPAP therapies in obstructive sleep apnoea: mandibular advancement device therapy

Dept of Orthodontics, Faculty of Medicine, Umeå University, Umeå, Sweden.
European Respiratory Journal (Impact Factor: 7.13). 11/2011; 39(5):1241-7. DOI: 10.1183/09031936.00144711
Source: PubMed

ABSTRACT Mandibular advancement devices (MADs) represent the main non-continuous positive airway pressure (non-CPAP) therapy for patients with obstructive sleep apnoea (OSA). The aim of the European Respiratory Society Task Force was to review the evidence in favour of MAD therapy. Effects of tongue-retaining devices are not included in this report. Custom-made MADs reduce apnoea/hypopnoea index (AHI) and daytime sleepiness compared with placebo devices. CPAP more effectively diminishes AHI, while increasing data suggest fairly similar outcomes in relation to symptoms and cardiovascular health from these treatments. Patients often prefer MADs to CPAP. Milder cases and patients with a proven increase in upper airway size as a result of mandibular advancement are most likely to experience treatment success with MADs. A custom-made device titrated from an initial 50% of maximum mandibular advancement has been recommended. More research is needed to define the patients who will benefit from MAD treatment compared with CPAP, in terms of the effects on sleep-disordered breathing and on other diseases related to OSA. In conclusion, MADs are recommended for patients with mild to moderate OSA (Recommendation Level A) and for those who do not tolerate CPAP. The treatment must be followed up and the device adjusted or exchanged in relation to the outcome.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Obstructive sleep apnoea (OSA) is a leading yet often undiagnosed cause of daytime sleepiness. It affects between 3 and 7% of the adult population, and the prevalence is expected to increase due to the obesity epidemic and ageing population. OSA is a sleep-related breathing disorder in which the airway completely (apnoea) or partly closes (hypopnea) during sleep at the end of expiration. This can lead to decreases in blood oxygen saturation and sleep fragmentation. Those who suffer with OSA are often unaware of their symptoms. Severe, untreated OSA can have serious implications such as an increased risk of cardio-vascular disease, motor vehicle accidents, poor neurocognitive performance and increased mortality. Many patients are pre-scribed continuous positive airway pressure (CPAP) as a treatment, but compliance with CPAP is often low. We briefly review the diagnosis and prognosis for obstructive sleep apnoea. But the main focus of our review is the critical evaluation of the numerous treatment strategies available for sleep apnoea as a multi-comorbid and multi-factorial condition. We also high-light areas that need further research.
    Bioscience Horizons 01/2014; 7. DOI:10.1093/biohorizons/hzu011
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Study Objectives: To perform a systematic review of the current evidence regarding the cardiovascular benefits of oral appliance (OA) therapy in obstructive sleep apnea (OSA) patients. Methods: A systematic review of relevant articles retrieved from online databases (PubMed, Web of Science, Medline, OvidSP) was conducted. All relevant studies published prior to January 20, 2013 that examined the effects of OA on any of the cardiovascular parameters were included. Results: OA therapy could have a beneficial effect on blood pressure (BP), endothelial function (EF), and left ventricular (LV) function of the heart. Eleven articles were included in this systematic review; 7 of 8 studies showed a significant reduction in BP with a mean BP decrease of 4.2 mm Hg, 2 studies showed significant improvement in EF, and 1 study showed significant improvement in LV heart function. Conclusion: OA therapy showed beneficial effects on the cardiovascular comorbidity in OSA patients. In studies comparing OA to CPAP therapy, effects of OA therapy were in the same order of magnitude as the effect of CPAP therapy. benefits of oral appliance therapy in obstructive sleep apnea: a systematic review. Journal of Dental Sleep Medicine 2015;2(1):9–14. O bstructive sleep apnea (OSA) is characterized by repeti-tive episodes of partial or total upper airway obstruction during sleep, resulting in a decrease of oronasal airflow. 1 OSA is acknowledged as a serious health problem, 2,3 and it is the most common sleep-related breathing disorder. The current prevalence estimates of moderate to severe sleep disordered breathing (apnea-hypopnea index [AHI], measured as events/ hour, ≥ 15) are 10% among 30-to 49-year-old men, 17% among 50-to 70-year-old men, 3% among 30-to 49-year-old women, and 9% among 50-to 70-year-old women. 4
    01/2015; 2(1):9-14. DOI:10.15331/jdsm.4430
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sleep-disordered breathing covers a broad range of central, obstructive or mixed respiratory disturbances occurring or aggravating during sleep. Treatment recommendations depend upon the underlying path-ophysiology and severity of the disorder, and therapy should be tailored to the individual patient's needs. • Before starting specific medical therapy, applicability of general measures such as dietary interventions or abstinence of drugs should be considered. • Continuous positive airway pressure (CPAP) is the mainstay for treatment of moderate to severe obstruc-tive sleep apnoea, whereas the use of oral appliances has been proved beneficial for mild to moderate disease. • Surgical treatment of pharyngeal anomalies, retrogna-thia or obesity may be applied in selected cases with obstructive sleep apnoea. • Central sleep apnoea is a heterogeneous condition that first requires identification and treatment of any underlying disease processes. Symptomatic treat-ment comprises CPAP, bi-level PAP or adaptive servo-ventilation and oxygen supplementation. SUMMARY This chapter deals with different therapeutic approaches to sleep disturbances characterized by sleep-disordered breathing. General recommendations and conservative measures are crucial first steps in the management of sleep-disordered breathing. Pharma-cological agents have no major role in the treatment of obstructive sleep apnoea, but have certain indications in patients with central sleep apnoea, especially in those suffering from heart failure. Treatment with oral devices has become a cornerstone in the management of patients with mild to moderate obstructive sleep apnoea, and may also be helpful in selected patients with severe disease. Positive airway pressure contin-ues to be the mainstay of treatment of obstructive sleep apnoea patients with moderate to severe disease. Bi-level positive airway pressure is indicated as a therapy for respiratory failure (alveolar hypoventilation with hypercapnia). Adaptive servo-ventilation has been introduced as a specific treatment of cardiac patients with central sleep apnoea and Cheyne–Stokes respi-ration, but may also be used in other conditions associated with central sleep apnoea. Surgery of the upper airways or of the maxillomandibular skeleton is performed in selected obstructive sleep apnoea patients. Bariatric surgery is a therapy indicated in morbidly obese patients with obstructive sleep apnoea who fail to lose weight with conservative measures such as hypocaloric diet and exercise training.
    Sleep Medicine Textbook, first edition edited by Claudio Bassetti, Zoran Dogas, Philippe Peigneux, 01/2014: chapter D.5 Treatment of respiratory sleep disorders: pages 259-274; European Sleep Research Society., ISBN: 9781119038931


Available from
Jun 1, 2014